ERBB2 and metastatic neoplasm: In fact, HER2 discordance between primary and metastatic tumors can be as high as 25% (2), and the limitations of single-site biopsies for heterogeneity may in part explain the mixed or discordant responses in some patients with HER2-positive mBC to HER2-targeted therapies.